|
Dr. Nicole Onetto joined ZymoGenetics as Senior Vice President and Chief Medical Officer in September 2005. Dr. Onetto has over fifteen years of clinical drug development experience at leading biotechnology and pharmaceutical companies. Previously Dr. Onetto was Executive Vice President and Chief Medical Officer at OSI Pharmaceuticals where she headed the Development Organization and led the registration program for Tarceva (TM). Prior to that Dr. Onetto served as Senior Vice President of Medical Affairs at Gilead Sciences and was also Senior Executive at Bristol-Myers Squibb in the oncology organization. While at BMS she was the International Project Leader for Taxol. She also held clinical research positions of increasing responsibility at NeXstar Pharmaceuticals Immunex and Hoechst. Dr. Onetto holds a Bachelor of Arts from the Academy of Paris (France) a Masters of Science in Pharmacology from the University of Montreal (Canada) a Doctor of Medicine degree from the University of Paris (France) and is qualified in pediatrics and hematology/oncology. | 